The IgA Nephropathy Foundation’s Post

Although it's essential to get new Alzheimer's disease (AD) treatments to the people who need them, drug development for AD is often considered too risky and lengthy. Read this white paper to learn about ways for AD clinical trials to overcome slow recruitment, improve enrollment and retention, and reach a representative sample of people with AD. #ClinicalTrials #AlzheimersClinicalTrials #AlzheimersResearch #HeadlandsResearch https://lnkd.in/eD7Hfbew

Although it's essential to get new Alzheimer's disease (AD) treatments to the people who need them, drug development for AD is often considered too risky and lengthy. Read this white paper to learn about ways for AD clinical trials to overcome slow recruitment, improve enrollment and retention, and reach a representative sample of people with AD. #ClinicalTrials #AlzheimersClinicalTrials #AlzheimersResearch #HeadlandsResearch https://lnkd.in/eZhuyu5f

𝗜𝗺𝗽𝗿𝗼𝘃𝗶𝗻𝗴 𝗗𝗿𝘂𝗴 𝗔𝗱𝗵𝗲𝗿𝗲𝗻𝗰𝗲 𝗶𝗻 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿'𝘀 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁!   Discover how Ingenious e-Brain developed a comprehensive treatment and funding strategy that enabled our client to significantly improve drug adherence for Alzheimer’s disease patients. By identifying patient access initiatives and overcoming barriers to treatment persistence, we helped increase the success of their innovative drug.   Read the full case study to see how our tailored approach helped the client address critical challenges and achieve their objectives: https://lnkd.in/gQ6FNdqP #alzheimerscare #healthcareinnovation #drugadherence #patientaccess #treatmentsuccess #pharmasolutions #innovativehealthcare #alzheimersawareness #healthcarestrategy #medtech #pharmaconsulting #patientengagement #lifesciences #chroniccare #futureproofingbusinesses

Bimekizumab's recent data, shown in the AAD 2024, highlighted two main clinical benefits: First, reducing skin pain, and second, inducing positive changes in draining tunnel count #hidradenitissuppurativa #dermatology #clinicalbenefit

🕒 Every day a trial is delayed, someone waits longer for treatment. For patients, these delays mean more pain, fewer options, or missed opportunities to fight their illness. It could be the mother battling cancer, the child with a rare disease, or the father awaiting a life-saving heart medication. At Clinergy Health, we understand the stakes and work to ensure every trial runs as efficiently as possible: * With an optimized 2-week site screening and feasibility process; * By proposing unique and innovative study designs and strategies; * Leveraging regulatory pathways to reduce approval bottlenecks. * Managing patient recruitment with cultural and logistical sensitivity. Offering quality oversight to keep trials on track and compliant. 🎤 What can the industry do better to prevent delays? Let’s brainstorm below. 💡 Dive deeper into how we support timely trials www.clinergyhealth.com #ClinergyHealth #CRO #Latam #ClinicalDevelopment #ClinicalTrials #EvidenceGeneration

#OBRxBrands #OurWorkWednesday STELARA® is a prescription medicine used to treat: – adults and children 6 years and older with moderate to severe psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills). – adults and children 6 years and older with active psoriatic arthritis. – adults 18 years and older with moderately to severely active Crohn’s disease. – adults 18 years and older with moderately to severely active ulcerative colitis. To Learn More: https://lnkd.in/eqHhMgqJ #OptiBrand #OptiBrandRx #OBRx #OWW #Pharma #PharmaMarketResearch #PharmaStrategy #strategy #marketresearch #getmore #PharmaExperts 

🌟 Seeking Assistance: In Search of VYLOY (Zolbetuximab) for Patient Treatment 🌟 Dear Connections, I hope this message finds you well. I'm reaching out to you today with an urgent request for assistance in locating a newly introduced medication called VYLOY™ (Zolbetuximab) by Astellas Pharma for one of our patients in need. Currently, we're caring for a patient diagnosed with metastatic gastric adenocarcinoma. Despite previous therapy regimens, our patient has not responded favorably. However, given their eligibility for treatment, particularly due to strong Claudin 18-2 expression, we are considering the potential benefits of VYLOY™. This medication, recently approved by the Ministry of Health in Japan, holds promise for our patient. While it's still under consideration by other approving agencies, we are eager to explore its potential in our patient's treatment plan. I'm reaching out to our network in the hope that someone may have insights, connections, or resources that could assist us in acquiring VYLOY™ for our patient. Any information or guidance you can provide regarding treatment with VYLOY™ would be immensely appreciated. Thank you for considering our request. Your support in this matter could make a significant difference in our patient's journey towards better health and well-being. Please feel free to reach out to me directly with any leads or information you may have. Email: hessami.amirhossein@gmail.com Warm regards, #Zolbetuximab #VYLOY #Astellas #TreatmentAccess #SupportiveCare #FindingACure #HealthAdvocacy #GlobalHealth #CancerAwareness #ClinicalTrials #ClinicalResearch #NewMedication #Healthcare #Oncology

A patient-led organization has just made an incredible breakthrough by repurposing a drug for a rare and deadly bleeding condition! Recently, a large clinical trial revealed that pomalidomide, originally developed for multiple myeloma, has proven effective in treating a life-threatening bleeding disorder called HHT (Hereditary Hemorrhagic Telangiectasia). This drug not only reduced bleeding events but also improved patients’ quality of life. Cure HHT brought together physicians, researchers, and patients to push this repurposing opportunity forward, showing the true power of patient-led organizations. At Every Cure, we aim to work closely with patient organizations to identify the most promising opportunities from our platform and ensure the necessary trials are conducted to benefit as many patients as possible. Because no one understands a rare disease better than those living with it. #raredisease #drugdevelopment #drugrepurposing #clinicaltrial

#Atrialfibrillation (#afib) affects more than 6 million Americans and increases the risk of #stroke by up to five times, according to the American Heart Association. While progress has been made, gaps in care remain. As September and #AfibAwarenessMonth come to a close, #AnthosTherapeutics proudly stands alongside advocacy groups such as StopAfib.org and the National Blood Clot Alliance for their daily efforts to raise awareness, educate, and advocate for patients. Research into therapies like #FactorXI inhibitors offers new hope for those living with atrial fibrillation. Learn more about Anthos Therapeutics and our clinical development program: 👉 https://bit.ly/4aR1QMf. #afibawareness #strokeawareness #thrombosis #hemostasis #innovation

What happens when you stop dupilumab treatment in patients 6mos-5years when they achieve clinical remission? This is a question we face in clinic all the time. Parents and caregivers always ask: can we stop? Now we some data to guide our discussions… #EAPS #EAPS2024 #poster #posterpresentation #atopicdermatitis #dupilumab